REAL-WORLD CHARACTERIZATION OF IPF AND PPF PATIENTS IN SPAIN: CLINICAL FEATURES, DIAGNOSIS AND HRQOL (RECOFIB STUDY)
Author(s)
Marina Tort, MSc Health Economics1, Cristina Moro, MD2, fatima rodriguez, PhD2, Silvia Armengol, Pharm, PhD1, Amanda Lopez Picado, Pharm, PhD3.
1Market Access, Boehringer Ingelheim España, S.A., Sant Cugat del Vallès, Spain, 2Medical Affairs, Boehringer Ingelheim España, S.A., Sant Cugat del Vallès, Spain, 3Real World Evidence, Boehringer Ingelheim España, S.A., Sant Cugat del Vallès, Spain.
1Market Access, Boehringer Ingelheim España, S.A., Sant Cugat del Vallès, Spain, 2Medical Affairs, Boehringer Ingelheim España, S.A., Sant Cugat del Vallès, Spain, 3Real World Evidence, Boehringer Ingelheim España, S.A., Sant Cugat del Vallès, Spain.
OBJECTIVES: To describe clinical and patient characteristics, diagnosis and health‑related quality of life, in fibrotic ILD in Spain
METHODS: RECOFIB is a multicenter, non-interventional, ambispective study in Spain. Adults with IPF or non-IPF fibrotic ILD meeting PPF criteria were enrolled between Apr 2024-May 2025. Clinical and diagnostic characteristics, and HRQoL were evaluated from electronic medical records.
RESULTS: 245 patients were included (43.3% IPF; 56.7% PPF). Mean age was 70.2±8.6 years; 65.7% male. At baseline, mean FVC was 77.4±17.9%, worse in PPF than in IPF (82.7±17.1 vs 73.3±17.6 respectively; p<0.001) and 30% of patients required supplemental oxygen. Mean time from symptom onset to diagnosis was 27.6±34.7 months (19.3±28.3 IPF vs 33.9±37.8 PPF; p<0.001). The majority of patients were diagnosed using an HRCT. Additionally, other tests were performed as part of the diagnostic process: blood tests (91.4%) and pulmonary function tests (88.1%), while genetic testing (3.3%), cryobiopsy (14.3%) and surgical lung biopsy (14.8%) were the least used. At 6-months, follow-up relied mainly on pulmonary function tests (40.7%) and blood test (27.9%) with limited use of HRCT (14.2%) and chest X-ray (14.2%). At diagnosis, over half of patients were untreated. Mean time to antifibrotic initiation was 3.0±5.3 months (1.9±4.1 IPF vs 3.9±6.0 PPF; p<0.001). At 6 months, 85.4% had received antifibrotics (93.5% IPF vs 79.1% PPF; p<0.001), with 8.9% permanently discontinuing (5.8 IPF vs 11.4 PPF; p<0.001). Patients reported a substantial overall HRQoL burden, as reflected by the L‑PF total score, which was significantly higher in PPF than in IPF (37.8±12.5 vs 32.2±10.20; p<0.001). This greater burden was consistently observed across HRQoL domains, including higher dyspnea, symptom burden, and daily life impact.
CONCLUSIONS: Diagnostic delays, variability in clinical management and HRQoL burden reflect a substantial disease impact and highlight the need for improved disease management and healthcare pathways.
METHODS: RECOFIB is a multicenter, non-interventional, ambispective study in Spain. Adults with IPF or non-IPF fibrotic ILD meeting PPF criteria were enrolled between Apr 2024-May 2025. Clinical and diagnostic characteristics, and HRQoL were evaluated from electronic medical records.
RESULTS: 245 patients were included (43.3% IPF; 56.7% PPF). Mean age was 70.2±8.6 years; 65.7% male. At baseline, mean FVC was 77.4±17.9%, worse in PPF than in IPF (82.7±17.1 vs 73.3±17.6 respectively; p<0.001) and 30% of patients required supplemental oxygen. Mean time from symptom onset to diagnosis was 27.6±34.7 months (19.3±28.3 IPF vs 33.9±37.8 PPF; p<0.001). The majority of patients were diagnosed using an HRCT. Additionally, other tests were performed as part of the diagnostic process: blood tests (91.4%) and pulmonary function tests (88.1%), while genetic testing (3.3%), cryobiopsy (14.3%) and surgical lung biopsy (14.8%) were the least used. At 6-months, follow-up relied mainly on pulmonary function tests (40.7%) and blood test (27.9%) with limited use of HRCT (14.2%) and chest X-ray (14.2%). At diagnosis, over half of patients were untreated. Mean time to antifibrotic initiation was 3.0±5.3 months (1.9±4.1 IPF vs 3.9±6.0 PPF; p<0.001). At 6 months, 85.4% had received antifibrotics (93.5% IPF vs 79.1% PPF; p<0.001), with 8.9% permanently discontinuing (5.8 IPF vs 11.4 PPF; p<0.001). Patients reported a substantial overall HRQoL burden, as reflected by the L‑PF total score, which was significantly higher in PPF than in IPF (37.8±12.5 vs 32.2±10.20; p<0.001). This greater burden was consistently observed across HRQoL domains, including higher dyspnea, symptom burden, and daily life impact.
CONCLUSIONS: Diagnostic delays, variability in clinical management and HRQoL burden reflect a substantial disease impact and highlight the need for improved disease management and healthcare pathways.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO224
Topic
Clinical Outcomes
Topic Subcategory
Clinician Reported Outcomes
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)